Ding Y, Yu Y
Mol Med Rep. 2025; 31(4).
PMID: 40017144
PMC: 11884236.
DOI: 10.3892/mmr.2025.13474.
Yu X, Xu H, Xing Y, Sun D, Li D, Shi J
Int J Mol Sci. 2025; 26(4).
PMID: 40003874
PMC: 11855757.
DOI: 10.3390/ijms26041408.
Saler C, Shuai S, Beckervordersandforth J, Rennspiess D, Roemen G, Gevers T
Cancer Rep (Hoboken). 2025; 8(2):e70127.
PMID: 39953652
PMC: 11828739.
DOI: 10.1002/cnr2.70127.
Wu Q, Chen Q, Yang J, Zhang J, Yang A
Chin Herb Med. 2025; 17(1):127-138.
PMID: 39949800
PMC: 11814253.
DOI: 10.1016/j.chmed.2024.04.002.
Andrade R, Perez-Rojas J, da Silva S, Miskinyte M, Quaresma M, Frazao L
Cancers (Basel). 2025; 17(3).
PMID: 39941867
PMC: 11816190.
DOI: 10.3390/cancers17030500.
The Clinical Characteristics, Patterns of Recurrence, and Long-Term Survival Outcomes of Dual-Phenotype Hepatocellular Carcinoma After Curative Liver Resection.
Yu Z, Fang Z, Yu Y, Liu S, Wang K, Shi Z
J Hepatocell Carcinoma. 2025; 12:183-192.
PMID: 39902378
PMC: 11789503.
DOI: 10.2147/JHC.S493094.
Advances and challenges in molecular understanding, early detection, and targeted treatment of liver cancer.
Shi J, Zhu X, Yang J
World J Hepatol. 2025; 17(1):102273.
PMID: 39871899
PMC: 11736488.
DOI: 10.4254/wjh.v17.i1.102273.
Diagnostic accuracy of preoperative MRI in assessing macrotrabecular-massive subtype of hepatocellular carcinoma: a systematic review and meta-analysis.
Zhou T, Han X, Xiao C, Lei X, Lan X, Wei X
Eur Radiol. 2025; .
PMID: 39836200
DOI: 10.1007/s00330-024-11344-9.
Quantitative proteomic analysis unveils a critical role of VARS1 in hepatocellular carcinoma aggressiveness through the modulation of MAGI1 expression.
Herman-Sanchez N, Del Rio-Moreno M, Ciria R, Sanchez-Frias M, Fernandez-Barrena M, Uriarte I
Mol Cancer. 2025; 24(1):15.
PMID: 39810176
PMC: 11731432.
DOI: 10.1186/s12943-024-02206-5.
Multifaceted Aspects of Dysfunctional Myelopoiesis in Cancer and Therapeutic Perspectives with Focus on HCC.
Arleo A, Montagner A, Giovannini C, Suzzi F, Piscaglia F, Gramantieri L
Biomolecules. 2025; 14(12.
PMID: 39766202
PMC: 11673139.
DOI: 10.3390/biom14121496.
Asynchronous Transitions from Hepatoblastoma to Carcinoma in High-Risk Pediatric Tumors.
Yu X, Sarabia S, Urbicain M, Somvanshi S, Patel R, Tran T
bioRxiv. 2025; .
PMID: 39763896
PMC: 11703271.
DOI: 10.1101/2024.12.24.630261.
Noninvasive identification of proliferative hepatocellular carcinoma on multiphase dynamic CT: quantitative and LI-RADS lexicon-based evaluation.
Zhang W, Li N, Li J, Zhao Y, Long Y, He C
Eur Radiol. 2024; .
PMID: 39665988
DOI: 10.1007/s00330-024-11247-9.
NR4A3 inhibits the tumor progression of hepatocellular carcinoma by inducing cell cycle G0/G1 phase arrest and upregulation of CDKN2AIP expression.
Zhao X, Min X, Wang Z, Chen X, Ge C, Zhao F
Int J Biol Sci. 2024; 20(15):5850-5867.
PMID: 39664575
PMC: 11628324.
DOI: 10.7150/ijbs.95174.
Global trends in machine learning applied to clinical research in liver cancer: Bibliometric and visualization analysis (2001-2024).
Zhuo E, Yang W, Wang Y, Tang Y, Wang W, Zhou L
Medicine (Baltimore). 2024; 103(49):e40790.
PMID: 39654222
PMC: 11631000.
DOI: 10.1097/MD.0000000000040790.
Deciphering the Prognostic and Therapeutic Value of a Gene Model Associated with Two Aggressive Hepatocellular Carcinoma Phenotypes Using Machine Learning.
Pan J, Zhang C, Huang H, Zhu Y, Zhang Y, Wu S
J Hepatocell Carcinoma. 2024; 11:2373-2390.
PMID: 39634327
PMC: 11614714.
DOI: 10.2147/JHC.S480358.
A histopathology-based artificial intelligence system assisting the screening of genetic alteration in intrahepatic cholangiocarcinoma.
Xiao H, Wang J, Weng Z, Lin X, Shu M, Shen J
Br J Cancer. 2024; 132(2):195-202.
PMID: 39623041
PMC: 11747625.
DOI: 10.1038/s41416-024-02910-5.
Outcomes of Bridging Therapy in Liver Transplantation for Hepatocellular Carcinoma.
Remiszewski P, Topolewski P, Laski D, Drobinska A
J Clin Med. 2024; 13(22).
PMID: 39597777
PMC: 11594365.
DOI: 10.3390/jcm13226633.
[Ga]Ga-PSMA-617 PET/MRI for imaging patients suspected of hepatocellular carcinoma.
Qin C, Song X, Sun S, Song Y, Ruan W, Gai Y
Eur J Nucl Med Mol Imaging. 2024; 52(4):1278-1290.
PMID: 39570398
DOI: 10.1007/s00259-024-06973-7.
Changes in alpha-fetoprotein across the systemic therapy continuum in advanced hepatocellular carcinoma-a real-world, multicenter study.
Li M, Hannan L, Goyal L, Bocobo A, Parks A, Bauer K
Ther Adv Med Oncol. 2024; 16:17588359241297085.
PMID: 39563717
PMC: 11574907.
DOI: 10.1177/17588359241297085.
Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma.
Bitar R, Salem R, Finn R, Greten T, Goldberg S, Chapiro J
Radiology. 2024; 313(2):e232875.
PMID: 39560477
PMC: 11605110.
DOI: 10.1148/radiol.232875.